rindopepimut + temozolomide

Rindopepimut + temozolomide is a combination therapy used for treating newly diagnosed, EGFRvIII-expressing glioblastoma. Rindopepimut (also known as CDX-110) is a vaccine targeting the EGFR deletion mutation EGFRvIII, consisting of an EGFRvIII-specific peptide conjugated to keyhole limpet haemocyanin. It is designed to stimulate an immune response against tumor cells expressing the EGFRvIII mutation. Temozolomide is a standard chemotherapy agent used in the treatment of glioblastoma. The combination was evaluated in multiple clinical trials, including the phase III ACT IV study, which ultimately did not demonstrate improved overall survival compared to temozolomide alone in patients with minimal residual disease.